HIGHLIGHTS
- who: Xiao-Yin Zhao from the The First Affiliated Hospital of China Medical University, China have published the Article: Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer, in the Journal: (JOURNAL)
- what: The main reason for therapy discontinuation was progressive disease in both groups, frontiersin.org 10.3389/fonc.2022.911160 CONSORT diagram.
- how: The results indicated that the TX-XELOX sequence is an acceptable strategy in MGC when compared with the XELOX-TX sequence. The results showed that DS . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.